谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC

T. Wehler,B. Wehler, H. Atmaca-Dirik,Christian Schulz,Christian Grohé, J. Topsch,A. Ehrlich

Journal of Thoracic Oncology（2021）

引用 0|浏览9
关键词
osimertinib,afatinib,egfr,first-line,mutation-positive
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要